Scientists have pinpointed a cellular death mechanism that may finally explain why neurons vanish in Alzheimer's disease and frontotemporal dementia, opening a potential pathway toward slowing these relentless conditions.
The process, called karyoptosis, describes what happens when toxic proteins accumulate inside a brain cell. Over time, the cell's nucleus shrivels and disintegrates, triggering the neuron's death. Researchers at King's College London, working with the UK Dementia Research Institute, identified this as a critical link between protein buildup and the brain cell loss that defines these diseases.
For decades, scientists knew that harmful proteins pile up in Alzheimer's and frontotemporal dementia brains. They also knew that neurons die as a result. But existing models of cell death, such as apoptosis, never fully accounted for the massive neuron loss observed in these conditions. The discovery of karyoptosis fills that gap.
To find evidence, researchers analyzed 3,000 brain cells from 28 patients with either frontotemporal dementia or advanced Alzheimer's disease. Using computational analysis, they detected karyoptosis occurring in 35 percent of cells from the frontal cortex in Alzheimer's patients, compared to just 15 percent in healthy older brains. The findings appear in Nature Communications.
The work pinpoints a molecular control switch that could become a drug target. When toxic proteins clump together inside neurons, they destabilize the nucleus membrane. A protein called p38 MAP kinase interacts with another protein, LaminB1, to execute this nuclear breakdown. In laboratory experiments using rat neurons, blocking these molecular switches reduced markers of karyoptosis.
"By specifically targeting the interaction between p38 MAP kinase and LaminB1 we may slow down the process of cell death, buying time for more pinpointed therapies against specific neurodegenerative diseases," said Dr. Manolis Fanto, a researcher at King's College London.
The team's next goal is to develop treatments that can selectively block this interaction in human patients. If successful, such therapies could potentially delay or prevent the cascade of brain cell death that robs patients of memory and other cognitive functions.
Dr. Rebecca Casterton, the study's lead author, described the work as laying out a road map for future breakthroughs. "The death and loss of cells in the brain drives many symptoms experienced by people living with dementia. Our study uncovers a new series of chemical events which can coordinate cell death in brain cells," she said.
The research was funded primarily by Alzheimer's Research UK and the Biotechnology and Biological Sciences Research Council International Partnership, with additional support from the UK Medical Research Council and UK Dementia Research Institute.
Author Jessica Williams: "This discovery transforms how we think about dementia progression and hands researchers a concrete target to go after, which is exactly what the field has been waiting for."
Comments